Anti-angiogenesis drugs in lung cancer

被引：6

作者：

Lee, Siow Ming ^{[1
,2
,3
]}

Baas, Paul ^{[4
]}

Wakelee, Heather ^{[5
]}

机构：

[1] Univ Coll London Hosp, NHS Trust, London NW1 2PG, England

[2] UCL Canc Inst, London, England

[3] Univ Coll Hosp, Dept Oncol, London, England

[4] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[5] Stanford Univ, Dept Med, Stanford Canc Ctr, Div Oncol, Stanford, CA 94305 USA

来源：

RESPIROLOGY | 2010年 / 15卷 / 03期

关键词：

bevacizumab; lung cancer; VEGF; anti-angiogenesis; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; ENDOTHELIAL-CELLS; DOUBLE-BLIND; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; COMBINATION; THERAPY; PLACEBO;

D O I：

10.1111/j.1440-1843.2010.01715.x

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

In the last years much attention has been given to the implementation of the so-called targeted drugs. One of the targets of tumours is the vasculature and this has led to the development of anti-angiogenic drugs. In lung cancer the use of these drugs has resulted in both positive and negative studies. In this paper the pros and cons are presented. We hope that this information will help the physician in making a proper treatment choice.

引用

页码：387 / 392

页数：6

共 33 条

[1] Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
Bremnes, RM
Camps, C
Sirera, R
[J]. LUNG CANCER, 2006, 51 (02) : 143 - 158
[2] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, Tudor
Brodowicz, Thomas
Zielinski, Christoph
Kim, Joo Hang
Krzakowski, Maciej
Laack, Eckart
Wu, Yi-Long
Bover, Isabel
Begbie, Stephen
Tzekova, Valentina
Cucevic, Branka
Pereira, Jose Rodrigues
Yang, Sung Hyun
Madhavan, Jayaprakash
Sugarman, Katherine P.
Peterson, Patrick
John, William J.
Krejcy, Kurt
Belani, Chandra P.
[J]. LANCET, 2009, 374 (9699) : 1432 - 1440
[3] De Boer R, 2009, J CLIN ONCOL, V27
[4] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Gatzemeier, Ulrich
Pluzanska, Anna
Szczesna, Aleksandra
Kaukel, Eckhard
Roubec, Jaromir
De Rosa, Flavio
Milanowski, Janusz
Karnicka-Mlodkowski, Hanna
Pesek, Milos
Serwatowski, Piotr
Ramlau, Rodryg
Janaskova, Terezie
Vansteenkiste, Johan
Strausz, Janos
Manikhas, Georgy Moiseevich
Von Pawel, Joachim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1545 - 1552
[5] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
Giaccone, G
Herbst, RS
Manegold, C
Scagliotti, G
Rosell, R
Miller, V
Natale, RB
Schiller, JH
von Pawel, J
Pluzanska, A
Gatzemeier, M
Grous, J
Ochs, JS
Averbuch, SD
Wolf, MK
Rennie, P
Fandi, A
Johnson, DH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 777 - 784
[6] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Goldstraw, Peter
Crowley, John
Chansky, Kari
Giroux, Dorothy J.
Groome, Patti A.
Rami-Porta, Ramon
Postmus, Pieter E.
Rusch, Valerie
Sobin, Leslie
[J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
[7] HAINSWORTH J, 2008, J THORAC ONCOL, V12, P1487
[8] Herbst RS, 2009, J CLIN ONCOL, V27
[9] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
Herbst, RS
Giaccone, G
Schiller, JH
Natale, RB
Miller, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 785 - 794
[10] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, RS
Prager, D
Hermann, R
Fehrenbacher, L
Johnson, BE
Sandler, A
Kris, MG
Tran, HT
Klein, P
Li, X
Ramies, D
Johnson, DH
Miller, VA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5892 - 5899

← 1 2 3 4 →